Balancing Price Reductions with Future R&D Investments

28 days ago

SPEAKER_03 / SPEAKER_05

"We've led in reducing the out-of-pocket costs from, it was originally $1,000. Now it's $499 ... But here's the risk... if we cut the price too low, there will be no more new medicines in this category."

The CEO addresses Eli Lilly’s strategy to cut drug prices to improve patient access while simultaneously investing heavily in R&D. By lowering the cost to consumers gradually, the company seeks to balance immediate market competitiveness with the need to sustain innovation and future growth. This nuanced strategy offers investors compelling insights into how pricing pressures can coexist with reinvestment in breakthrough therapies.

Related Stocks